Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $264K fell 41.1% year over year, behind the -26.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 27.7% from the prior quarter. Over 3 fiscal years it compounded at -22.8% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -41.1% toward the trailing-twelve-month pace of -26.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.7M USD
- Year-over-year change
- -20.2%
- 4-year CAGR
- +2.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.7M | -20.2% |
| FY2024 | 2024-12-31 | 2.13M | +15.4% |
| FY2023 | 2023-12-31 | 1.84M | -50.0% |
| FY2022 | 2022-12-31 | 3.68M | +139.8% |
| FY2021 | 2021-12-31 | 1.54M | — |
Depreciation & Amortization vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 depreciation & amortization of $1.51M is the 4th highest of the 10 companies compared; the peer median is $1.12M.
- Its year-over-year change of -26.6% is the 7th highest of 10, against a peer median of -11.2%.
- Over three fiscal years its annual growth of -22.8% compares with a peer median of -4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $6.7M | -8.9% | -4.0% | 6.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.64M | +6.6% | +30.9% | — |
| LTM Mar 2026 | $1.51M | -26.6% | -22.8% | — | |
| LTM Mar 2026 | $1.45M | -11.2% | +13.6% | 1079.1% | |
| LTM Mar 2026 | $1.12M | +22.5% | +35.7% | — | |
| LTM Mar 2026 | $628K | -48.8% | -19.7% | — | |
| LTM Mar 2026 | $167K | -73.0% | -39.9% | 2.3% | |
| LTM Mar 2026 | $23.33K | -14.7% | +0.0% | 0.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $22K | -88.5% | -20.8% | — |
| Peer median (excluding PLRX) | $1.12M | -11.2% | -4.0% | 4.5% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| Weighted Avg Shares | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
| Weighted Avg Shares (Diluted) | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.